Cancer-related fatigue in carcinoma urinary bladder patients receiving chemotherapy: A single institutional study from northern India.

2019 ◽  
Vol 37 (7_suppl) ◽  
pp. 361-361
Author(s):  
Vineet Talwar ◽  
Varun Goel ◽  
Prasanta DASH
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Urinary Bladder ◽  
Clinical Intervention ◽  
Fear Of Pain ◽  
Cancer Related Fatigue ◽  
Northern India ◽  
Clinically Significant ◽  
Loss Of Appetite

361 Background: Fatigue is one of the most disabling phenomenon among patients receiving anti cancer treatment, which has profound effect on their Quality of life (QOL). Although clinicians across the globe acknowledge the importance of regular assessment of fatigue, however it is seldom being assessed and documented in clinical practice in India and very few studies have reported Cancer Related Fatigue among Indian population. Methods: For this study an exploratory design was adopted, using a purposive sampling method. Patients (N=206,) undergoing chemotherapy at Rajiv Gandhi Cancer Hospital and Research Center, Delhi, India; aged 18-83 years were included. The level of fatigue was assessed using 16- item Multidimensional assessment of Fatigue (MAF) scale and a semi structured in depth interview schedule. These interviews were recorded, transcribed and analyzed. Results: Irrespective of age, and education, 81% patients experience clinically significant fatigue. Extreme level of fatigue was reported by 29% patients requiring immediate clinical intervention while 52% patients reported moderate level of clinically significant fatigue. Top four psychosocial issues reported were: apprehension of CT side effects (23.5%), fear of pain (19%), Loss of appetite (17.5%) and anxiety during CT (13.5 %), followed by financial issues (11%). Among all patients, (49.5%) were aware of their diagnosis of which 8% were either fully aware or partially aware about the prognosis (23%). Conclusions: Fatigue remains one of the most important clinical parameters among majority of Carcinoma Urinary Bladder patients receiving chemotherapy, and is neither assessed by clinicians nor reported by majority of the patients. While almost one fourth of the patients report fear of chemotherapy as their pressing psychosocial concern, others report fear of pain, loss of appetite, manifest anxiety symptoms or report financial and logistics issue during CT. Various exercise, educational material and psychotherapeutic interventions should be developed to prepare and support them during their treatment for better preparedness of side effects and their management, reduced symptoms and better quality of life.

scholarly journals When Eating Becomes Torturous: Understanding Nutrition-Related Cancer Treatment Side Effects among Individuals with Cancer and Their Caregivers

Nutrients ◽  
2022 ◽  
Vol 14 (2) ◽  
pp. 356
Author(s):  
Brandy-Joe Milliron ◽  
Lora Packel ◽  
Dan Dychtwald ◽  
Cynthia Klobodu ◽  
Laura Pontiggia ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Cancer Treatment ◽  
Food Preferences ◽  
Treatment Side Effects ◽  
Food And Nutrition ◽  
Loss Of Appetite ◽  
Living With Cancer ◽  
Depth Interviews

Individuals living with cancer often experience multiple nutrition-related side effects from cancer treatment, including changes in taste and smell, nausea, diarrhea, loss of appetite, and pain during eating. These side effects can profoundly impact nutritional status and quality of life. The purpose of this study was to explore experiences with nutrition-related cancer treatment side effects among cancer patients and their family caregivers, the way they manage such side effects, and the resulting changes in food preferences and behaviors. Structured surveys and in-depth interviews were conducted. Interviews focused on the presence and management of treatment side effects, how those changes influenced food preferences, and the extent to which they interfered with quality of life. Most patients (72%) reported treatment side effects; 61% reported that these side effects impacted their eating and drinking. Common side effects included fatigue (58%), dry mouth (30%), nausea (24%), constipation (20%) and diarrhea (20%). Six overarching qualitative themes were identified: Spiral of side effects; Pain of eating; Burden of eating; Loss of taste/change in taste; Symptom management; and Solutions. The authors conclude with implications for food and nutrition practice—moving beyond traditional recommendations of what to eat or avoid—to consider the overall patient and caregiver experience.

Medications for Fatigue

2020 ◽  
pp. 217-242
Author(s):  
Andrew J. Roth ◽  
Christian J. Nelson
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Sleep Disturbances ◽  
Panic Attacks ◽  
Cancer Related Fatigue ◽  
Wide Range ◽  
Significant Depression

Cancer-related fatigue is common, occurring in up to 80% of patients. Distressing fatigue can be related to psychiatric or medical causes such as significant depression, frequent intense anxiety, or panic attacks, as well as sleep disturbances, pain, and electrolyte or hormonal abnormalities. It is often caused by a wide range of medications and substances. This chapter presents the various causes of fatigue to help non-prescribing clinicians distinguish fatigue from other look-alike diagnoses such as depression and make appropriate referrals to prescribers. Identifying opportunities to supplement nonpharmacologic therapies with an activating medication can improve a patient’s quality of life and joy in living. This chapter will help all clinicians become more aware of medications used to boost energy, such as energizing antidepressants, wakefulness agents, and psychostimulants, as well as the potential side effects of these medications.

scholarly journals Symbicort in steroid-dependent asthma: reduction of oral steroids requirements

2005 ◽  
pp. 71-79
Author(s):  
S. N. Avdeev ◽  
Z. S. Etteeva ◽  
N. A. Voznesensky ◽  
N. N. Mesheriakova ◽  
A. G. Chuchalin
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Stability Criteria ◽  
Short Acting ◽  
Asthma Symptoms ◽  
Steroid Dependent ◽  
Severity Scores ◽  
Oral Steroids ◽  
Clinically Significant

Objective: to study the ability of inhaled Symbicort to reduce daily oral steroids (OS) requirements in patients with severe steroid-dependent asthma. Methods: 16 patients with severe steroid-dependent asthma were included into the study (5 males, 11 females, mean age 53 ± 8 years, mean dose of OS 10.9 ± 5.2 mg / day, mean OS treatment duration 9.3 ± 4.1 years, mean FEV1 59.3 ± 15.1%). All patients received Symbicort administered by means of a multidose poder inhaler 4.5 / 160 mkg 2 inhalations twice daily, every 2 weeks patients underwent controlled OS reduction on the basis of predetermined asthma stability criteria. Results: OS was eliminated or reduced in 14 patients (87.5 %), the OS dose was reduced to 3.3 ± 6.8 mg / day (р < 0.001). At the end of 12 weeks of Symbicort therapy FEV1 and FVC increased by 18.6 % and 8.9 %, respectively. Daytime and nighttime asthma symptom severity scores improved in average by 1 point (р < 0.001). The number of inhalations of short-acting β2-agonists reduced from 3.4 ± 1.7 to 1.5 ± 1.3 puffs / day (р < 0.001). Statistically and clinically significant improvements were seen in all 4 domains of quality of life scores (AQLQ) (р < 0.001). The level of NOex reduced significantly form 18.6 ± 11.4 ppb at baseline to 7.9 ± 2.8 ppb after 12 weeks (р = 0.001). The side effects of OS were reduced to the end of study. Conclusion: in patients with severe steroid-dependent asthma therapy with Symbicort allows to eliminate or reduce OS therapy with improved lung function, improved daytime and nighttime asthma symptoms, improved asthma-specific quality of life, reduction of short-acting β2-agonists use and reduction of side effects of OS.

Pain and other symptoms in patients with hepatocellular carcinoma (HCC): A qualitative analysis.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. e15187-e15187 ◽  
Author(s):  
Zeeshan Butt ◽  
Rajiv Mallick ◽  
Mary Frances Mulcahy ◽  
Al B. Benson ◽  
David Cella ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Back Pain ◽  
Side Effects ◽  
Systemic Therapy ◽  
Liver Diseases ◽  
Lower Back ◽  
Ongoing Pain ◽  
Pain Symptoms ◽  
Loss Of Appetite

e15187 Background: HCC is the second leading cause of cancer related deaths worldwide and incidence is increasing. Most HCC patients are diagnosed late-stage and with pain. Understanding the nature of pain experienced by HCC patients is complicated by co-morbid (including other liver) diseases and treatment related pain. The purpose of this study was to identify pain symptoms that are important and relevant to HCC patients who have received systemic therapy. Methods: We conducted semi-structured thematic interviews with 10 HCC patients who were currently on or previously had received oral systemic therapy (e.g., sorafenib) and had not received local or loco-regional therapy (e.g., surgery, radiation or chemo-embolization) within 4 weeks of the interview. Interviews included open elicitation of key symptoms, side effects and concerns. Patients also completed selected pain items from the FACT-Hep; items had previously been validated for patients with hepatobiliary cancers. Results: Mean age was 58 years (range 33-77); 2 patients had co-morbid cirrhosis, 1 had co-morbid hepatitis, and 4 patients had cirrhosis and hepatitis. When asked to describe the symptoms, side-effects or other issues that most significantly impact their quality of life, patients most often mentioned fatigue (n=5), diarrhea (n=5), skin toxicities (n=5), and loss of appetite (n=4). Nine patients reported experiencing pain over their HCC treatment course. Abdomen (N=7) and lower back (N=3) were the most common sites of pain; 2 patients reported only experiencing temporary pain from prior chemoembolization. The other 7 patients experienced ongoing pain, partly attributed to systemic therapy, ascites, or metastases. Ongoing abdominal and back pain were frequently not attributed to a specific cause. All patients indicated that FACT-Hep items adequately assessed their pain. Conclusions: Although pain was not a major driver of quality of life and for a few HCC patients it was transient and treatment-related, the majority of patients experienced some persistent pain. Abdominal pain and back pain were the most common pain sites for HCC patients. These results support the relevance of pain symptoms that have been previously identified as important in HCC.

▾ Lamotrigine – an add-on antiepileptic

1992 ◽  
Vol 30 (19) ◽  
pp. 75-76
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Antiepileptic Drug ◽  
Partial Seizures ◽  
First Line ◽  
Low Level ◽  
Clonic Seizures ◽  
Clinically Significant ◽  
The Brain

Lamotrigine (Lamictal – Wellcome) is a new antiepileptic drug. It is licensed as ‘add-on’ treatment for patients with partial seizures, either localised to one part of the brain or spreading to tonic-clonic seizures (secondarily generalised), who are not satisfactorily controlled with first-line drugs. The manufacturer claims that it “offers the hope of an improved quality of life” while having “a low level of clinically significant side-effects”. We examine these claims.

scholarly journals Metode Terapi Hipnopunktur (Hipnoterapi Dan Terapi Akupunktur) Untuk Peningkatan Kualitas Hidup Pasien Kanker Rahim Pasca Kemoterapi Di Kota Surakarta

2016 ◽  
Vol 1 (1) ◽  
Author(s):  
Maria Dewi Christiyawati ◽  
Sri Yatmihatun ◽  
Sumanto Sumanto
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Uterine Cancer ◽  
Uterine Sarcoma ◽  
T Test ◽  
Control Group ◽  
Significant Difference ◽  
Loss Of Appetite ◽  
Myoma Uteri

Abstract: Uterine Cancer Is A Gynecologic Malignancy Is Most Common In Women, One Of Its Kind Is A Uterine Sarcoma. Uterine sarcoma is a rare tumor that dominates 3% of uterine cancer. Myoma uteri can cause malignancy although his case is rare. In Indonesia, the proportion of myoma uteri reach 2.39 to 11.7% of all gynecological patients. Chemotherapy is a treatment for uterine cancer drugs of the use of drugs to kill or slow the growth of cancer cells that can cause side effects. The side effects that can be felt by people with cancer of the uterus such as feeling sick, vomiting, feeling tired, weight loss, hair loss, loss of appetite and difficulty sleeping. Approximately 70-100% of chemotherapy patients experience fatigue / fatigue. Fatigue felt by patients with this cancer will also affect the quality of life penderita.Terapi acupuncture in cancer patients can be done to overcome the side effects of chemotherapy either by research or classical theory. The research method was quasi experimental design with pre -post test design without control group. Data were taken before and after administration of therapeutic intervention hipnopunctur. Data dianlisis using t-test, independent t-test multiple linear regression. Number of samples 14 people. Results obtained significance value (p) = 0.000 compared with the value ᾳ = 0:05 (5%), where the value of P <0.05, which means that a significant difference between the methods Hipnopunkture with improved quality of life. Values obtained -0824 t test. The value of the coefficient is between 0.8 -1.0 interval which indicates the degree of influence between these variables is very strong.

scholarly journals Clinical characteristics and quality of life among Sri Lankan patients with chronic pancreatitis

2020 ◽  
Vol 48 (12) ◽  
pp. 030006052097987
Author(s):  
Umesh Jayarajah ◽  
Thisaru Widyarathne ◽  
Metthananda Nawarathne ◽  
Sivananthan Raguvaran ◽  
Nishanthan Subramaniam ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Weight Loss ◽  
Chronic Pancreatitis ◽  
Clinical Characteristics ◽  
Considerable Proportion ◽  
Intractable Pain ◽  
Life Questionnaire ◽  
European Organization ◽  
Loss Of Appetite

Objective We aimed to describe the clinical characteristics of chronic pancreatitis (CP) and patient quality of life (QOL) in a resource-limited setting. Methods We performed a cross-sectional study including patients with clinical and radiological features of CP. We collected clinical data and assessed QOL using the European Organization for the Research and Treatment of Cancer Quality of Life Questionnaire. Results We included 103 patients (median age 44 years, 84 men). Median age at symptom onset was 36 (4–78) years. Around 70% of patients had diabetes mellitus and 62.1% had consumed alcohol; 36 (35%) were current smokers. The mean overall global QOL score was 68.7. Most patients (91.3%) sought treatment from multiple centers. Nineteen (18.5%) had pancreatic stone disease, 38 (36.9%) had persistent abdominal pain (median severity 7.8/10, 59 (57.3%) had steatorrhea, and 56 (54.4%) had jaundice. Poor QOL was significantly associated with weight loss, loss of appetite, and intractable pain. No correlation with age, sex, or alcohol consumption was noted. Conclusion A considerable proportion of patients with CP had troublesome symptoms. Intractable pain, loss of appetite, and weight loss were significantly associated with poor QOL. Further assessment is needed of patients’ psychosocial well-being and its association with QOL.

Proton Pump Inhibitors in 2021: Pros, Cons, and Everything in Between

2021 ◽  
pp. 263451612110217
Author(s):  
Joshua A. Sloan ◽  
Philip O. Katz
Keyword(s):  
Quality Of Life ◽  
Side Effects ◽  
Adverse Events ◽  
Proton Pump Inhibitors ◽  
Proton Pump ◽  
Drug Class ◽  
Life Threatening

The medical and lay literature has exploded with reports of adverse events associated with proton pump inhibitors over the last 10 to 15 years. The dissemination of these reports to patients and clinicians have created substantial concerns regarding what has been an exceptionally valuable drug class, dramatically improving patient quality of life, and in many cases preventing life threatening side effects of other medication. Patients are more frequently seeking to avoid these medications, and practitioners are reducing or discontinuing them to the patient’s detriment due to a misunderstanding of the data. This review will discuss the data regarding the most commonly publicized adverse events and attempt to put them in perspective.

scholarly journals Quality of life, symptoms and dietary habits in oncology outpatients with malnutrition: A cross-sectional study

2021 ◽  
Vol 38 (2) ◽  
Author(s):  
Mira Sonneborn-Papakostopoulos ◽  
Clara Dubois ◽  
Viktoria Mathies ◽  
Mara Heß ◽  
Nicole Erickson ◽  
...  
Keyword(s):  
Quality Of Life ◽  
At Risk ◽  
Side Effects ◽  
Dietary Habits ◽  
Nutritional Assessment ◽  
Mini Nutritional Assessment ◽  
University Hospital ◽  
Cross Sectional ◽  
European Organization

AbstractCancer-related malnutrition has a high prevalence, reduces survival and increases side effects. The aim of this study was to assess oncology outpatients and risk of malnutrition. Reported symptoms and quality of life (QoL) in patients found to be at risk of malnutrition or malnourished were compared to patients without malnutrition. Using a standardized questionnaire, the European Organization for Research and Treatment of Cancer Questionnaire for Quality of Life and the Mini Nutritional Assessment (MNA), patients in an outpatient cancer clinic undergoing chemotherapy treatment at a German University Hospital were assessed for nutrition, risk of malnutrition and quality of life. Based on the MNA, 39 (45.9%) patients were categorized as malnourished or at risk for malnutrition. Loss of appetite (n = 37.6%, p < 0.001) and altered taste sensation (n = 30,3%, p < 0.001) were the symptoms most frequently associated with reduced food intake. Patients with risk of malnutrition scored lower on the global health status (n = 48.15%, p = 0.001). Side effects of cancer treatments lead to a higher risk of malnutrition and as a consequence lower QoL. These side effects should be addressed more efficiently in cancer care.

scholarly journals Estimating the minimum important difference in the DEMQOL instrument in people with dementia

2021 ◽  
Author(s):  
Ellen C. Lee ◽  
Jessica Wright ◽  
Stephen J. Walters ◽  
Cindy L. Cooper ◽  
Gail A. Mountain
Keyword(s):  
Quality Of Life ◽  
Controlled Trial ◽  
Minimum Important Difference ◽  
Absolute Change ◽  
People With Dementia ◽  
Related Quality ◽  
Registration Number ◽  
Clinically Significant ◽  
Randomised Controlled

Abstract Purpose The Dementia-Related Quality of Life (DEMQOL) measure and the DEMQOL-Utility Score (DEMQOL-U) are validated tools for measuring quality of life (QOL) in people with dementia. What score changes translate to a clinically significant impact on patients’ lives was unknown. This study establishes the minimal important differences (MID) for these two instruments. Methods Anchor-based and distribution-based methods were used to estimate the MID scores from patients enrolled in a randomised controlled trial. For the anchor-based method, the global QOL (Q29) item from the DEMQOL was chosen as the anchor for DEMQOL and both Q29 and EQ-5D for DEMQOL-U. A one category difference in Q29, and a 0.07 point difference in EQ-5D score, were used to classify improvement and deterioration, and the MID scores were calculated for each category. These results were compared with scores obtained by the distribution-based methods. Results A total of 490 people with dementia had baseline DEMQOL data, of these 386 had 8-month data, and 344 had 12-month DEMQOL data. The absolute change in DEMQOL for a combined 1-point increase or decrease in the Q29 anchor was 5.2 at 8 months and 6.0 at 12 months. For the DEMQOL-U, the average absolute change at 8 and 12 months was 0.032 and 0.046 for the Q29 anchor and 0.020 and 0.024 for EQ-5D anchor. Conclusion We present MID scores for the DEMQOL and DEMQOL-U instruments obtained from a large cohort of patients with dementia. An anchored-based estimate of the MID for the DEMQOL is around 5 to 6 points; and 0.02 to 0.05 points for the DEMQOL-U. The results of this study can guide clinicians and researchers in the interpretation of these instruments comparisons between groups or within groups of people with dementia. Trial Registration Number and date of registration: ISRCTN17993825 on 11th October 2016.

Sign in / Sign up

Export Citation Format

Share Document